Anthos Therapeutics

Anthos Therapeutics has raised $250 million in funding, backed primarily by Blackstone Life Sciences, which helped launch the company in 2019 through a major private equity investment. The company was established to develop next-generation anticoagulants, addressing the bleeding risks associated with traditional therapies. Anthos Therapeutics’ lead program targets underserved segments like atrial fibrillation and cancer-associated thrombosis, leveraging strong clinical data and partnerships, including support from Novartis. With the acquisition completed and a small, focused team, Anthos continues to push forward with high-impact cardiovascular therapies, backed by strong investor support and clinical validation.